Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased dna damage and senescence

Stem Cells

Volumn 31, Issue 12, 2013, Pages 2813-2826

  Paschalaki, Koralia E ^a,b   Starke, Richard D ^a   Hu, Yanhua ^c   Mercado, Nicolas ^a   Margariti, Andriana ^c   Gorgoulis, Vassilis G ^b,d   Randi, Anna M ^a   Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Ataxia telangiectasia mutated kinase; Cellular senescence; DNA damage response; Endothelial progenitor cells; Sirtuin; Smoking

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; CD31 ANTIGEN; CIGARETTE SMOKE; HISTONE H2AX; PROTEIN P53; RESVERATROL; SIRTUIN 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ADULT; ANGIOGENESIS; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD OUTGROWTH ENDOTHELIAL CELL; CELL CYCLE ARREST; CELL SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; DEACETYLATION; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RNA INTERFERENCE; SENESCENCE; SMOKING; UPREGULATION; ADVERSE EFFECTS; AGED; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CELL AGING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; STEM CELL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL AGING; DNA DAMAGE; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA INTERFERENCE; SMOKING; STEM CELLS;

EID: 84890451565     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1488     Document Type: Article

References (90)

1. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275: 964-967.
2. Critser PJ, Voytik-Harbin SL, Yoder MC. Isolating and defining cells to engineer human blood vessels. Cell Prolif 2011;44 (suppl 1):15-21.
3. Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801-1809.
4. Fuchs S, Ghanaati S, Orth C et al. Contribution of outgrowth endothelial cells from human peripheral blood on in vivo vascularization of bone tissue engineered constructs based on starch polycaprolactone scaffolds. Biomaterials 2009;30:526-534.
5. Hendrickx B, Verdonck K, Van den Berge S et al. Integration of blood outgrowth endothelial cells in dermal fibroblast sheets promotes full thickness wound healing. Stem Cells 2010;28:1165-1177.
6. Kung EF, Wang F, Schechner JS. In vivo perfusion of human skin substitutes with microvessels formed by adult circulating endothelial progenitor cells. Dermatol Surg 2008;34:137-146.
7. Dudek AZ, Bodempudi V, Welsh BW et al. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer 2007;97:513-522.
8. Matsui H, Shibata M, Brown B et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells 2007;25:2660-2669.
9. Fernandez L, Sanz-Rodriguez F, Zarrabeitia R et al. Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res 2005;68:235-248.
10. Medina RJ, O'Neill CL, O'Doherty TM et al. Endothelial progenitors as tools to study vascular disease. Stem Cells Int 2012;346735:2012.
11. Starke RD, Ferraro F, Paschalaki KE et al. Endothelial von Willebrand factor regulates angiogenesis. Blood 2011;117:1071-1080.
12. Toshner M, Voswinckel R, Southwood M et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009;180:780-787.
13. Guven H, Shepherd RM, Bach RG et al. The number of endothelial progenitor cell colonies in the blood is increased in patients with angiographically significant coronary artery disease. J Am Coll Cardiol 2006;48:1579-1587.
14. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593-600.
15. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7.
16. Ballard VL, Edelberg JM. Stem cells and the regeneration of the aging cardiovascular system. Circ Res 2007;100:1116-1127.
17. Williamson K, Stringer SE, Alexander MY. Endothelial progenitor cells enter the aging arena. Front Physiol 2012;3:30.
18. Freund KM, Belanger AJ, D'Agostino RB et al. The health risks of smoking. The Framingham Study: 34 years of follow-up. Ann Epidemiol 1993;3:417-424.
19. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176: 532-555.
20. Schneider C, Bothner U, Jick SS et al. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010; 25:253-260.
21. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature. Chest 2005;127:1952-1959.
22. McAllister DA, Maclay JD, Mills NL et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176: 1208-1214.
23. Sabit R, Bolton CE, Edwards PH et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259-1265.
24. Fadini GP, Schiavon M, Cantini M et al. Circulating progenitor cells are reduced in patients with severe lung disease. Stem Cells 2006;24: 1806-1813.
25. Kondo T, Hayashi M, Takeshita K et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol 2004;24:1442-1447.
26. Michaud SE, Dussault S, Haddad P et al. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis 2006;187:423-432.
27. Palange P, Testa U, Huertas A et al. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J 2006;27:529-541.
28. Takahashi T, Suzuki S, Kubo H et al. Impaired endothelial progenitor cell mobilization and colony-forming capacity in chronic obstructive pulmonary disease. Respirology 2011;16:680-687.
29. Yue WS, Wang M, Yan GH et al. Smoking is associated with depletion of circulating endothelial progenitor cells and elevated pulmonary artery systolic pressure in patients with coronary artery disease. Am J Cardiol 2010;106:1248-1254.
30. Campisi J, d'Adda di FF. Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-740.
31. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-233.
32. Gorgoulis VG, Halazonetis TD. Oncogene-induced senescence: The bright and dark side of the response. Curr Opin Cell Biol 2010;22: 816-827.
33. Mahmoudi M, Mercer J, Bennett M. DNA damage and repair in atherosclerosis. Cardiovasc Res 2006;71:259-268.
34. Aoshiba K, Zhou F, Tsuji T et al. DNA damage as a molecular link in the pathogenesis of COPD in smokers. Eur Respir J 2012;39:1368-1376.
35. Bartkova J, Rezaei N, Liontos M et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006;444:633-637.
36. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913.
37. Caramori G, Adcock IM, Casolari P et al. Unbalanced oxidant-induced DNA damage and repair in COPD: A link towards lung cancer. Thorax 2011;66:521-527.
38. Amsellem V, Gary-Bobo G, Marcos E et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;184:1358-1366.
39. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence exacerbates pulmonary inflammation in patients with chronic obstructive pulmonary disease. Respiration 2010;80:59-70.
40. Martinet W, Knaapen MW, De Meyer GR et al. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002;106:927-932.
41. Gorgoulis VG, Pratsinis H, Zacharatos P et al. p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab Invest 2005;85:502-511.
42. Minamino T, Miyauchi H, Yoshida T et al. Endothelial cell senescence in human atherosclerosis: Role of telomere in endothelial dysfunction. Circulation 2002;105:1541-1544.
43. Minamino T, Komuro I. Vascular cell senescence: Contribution to atherosclerosis. Circ Res 2007;100:15-26.
44. Blanpain C, Mohrin M, Sotiropoulou PA et al. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 2011;8:16-29.
45. Liu L, Rando TA. Manifestations and mechanisms of stem cell aging. J Cell Biol 2011;193:257-266.
46. Mandal PK, Blanpain C, Rossi DJ. DNA damage response in adult stem cells: Pathways and consequences. Nat Rev Mol Cell Biol 2011; 12:198-202.
47. Sperka T, Wang J, Rudolph KL. DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 2012;13:579-590.
48. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009;460:587-591.
49. Oberdoerffer P, Michan S, McVay M et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008;135:907-918.
50. Nakamaru Y, Vuppusetty C, Wada H et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009; 23:2810-2819.
51. Rajendrasozhan S, Yang SR, Kinnula VL et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:861-870.
52. Mattagajasingh I, Kim CS, Naqvi A et al. SIRT1 promotes endotheliumdependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007;104:14855-14860.
53. Ota H, Akishita M, Eto M et al. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007;43:571-579.
54. Lavu S, Boss O, Elliott PJ et al. Sirtuins - Novel therapeutic targets to treat age-Associated diseases. Nat Rev Drug Discov 2008;7:841-853.
55. Milne JC, Lambert PD, Schenk S et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712-716.
56. Orimo M, Minamino T, Miyauchi H et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 2009;29: 889-894.
57. Rahman I, Kinnula VL, Gorbunova V et al. SIRT1 as a therapeutic target in inflammaging of the pulmonary disease. Prev Med 2012;54 (suppl):S20-S28.
58. Stein S, Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011;10:640-647.
59. Ingram DA, Mead LE, Tanaka H et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004;104:2752-2760.
60. Zhan H, Suzuki T, Aizawa K et al. Ataxia telangiectasia mutated (ATM)-mediated DNA damage response in oxidative stress-induced vascular endothelial cell senescence. J Biol Chem 2010;285:29662-29670.
61. Tanaka T, Halicka HD, Huang X et al. Constitutive histone H2AX phosphorylation and ATM activation, the reporters of DNA damage by endogenous oxidants. Cell Cycle 2006;5:1940-1945.
62. Lukas C, Savic V, Bekker-Jensen S et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol 2011;13:243-253.
63. Kao CL, Chen LK, Chang YL et al. Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation. J Atheroscler Thromb 2010;17:970-979.
64. Ota H, Eto M, Ogawa S et al. SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. J Atheroscler Thromb 2010;17:431-435.
65. Zu Y, Liu L, Lee MY et al. SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells. Circ Res 2010;106:1384-1393.
66. Vaziri H, Dessain SK, Ng EE et al. hSIR2(SIRT1) functions as an NAD-dependent p 53 deacetylase. Cell 2001;107:149-159.
67. Gorospe M, de Cabo R. AsSIRTing the DNA damage response. Trends Cell Biol 2008;18:77-83.
68. Yuan Z, Zhang X, Sengupta N et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell 2007;27:149-162.
69. Yuan J, Luo K, Liu T et al. Regulation of SIRT1 activity by genotoxic stress. Genes Dev 2012;26:791-796.
70. Au P, Daheron LM, Duda DG et al. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood 2008;111:1302-1305.
71. Melero-Martin JM, Khan ZA, Picard A et al. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood 2007;109:4761-4768.
72. Margariti A, Winkler B, Karamariti E et al. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci USA 2012;109:13793-13798.
73. Chen J, Goligorsky MS. Premature senescence of endothelial cells: Methusaleh's dilemma. Am J Physiol Heart Circ Physiol 2006;290: H1729-H1739.
74. Erusalimsky JD. Vascular endothelial senescence: From mechanisms to pathophysiology. J Appl Physiol 2009;106:326-332.
75. Ingram DA, Krier TR, Mead LE et al. Clonogenic endothelial progenitor cells are sensitive to oxidative stress. Stem Cells 2007;25:297-304.
76. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006;174: 886-893.
77. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009;135:173-180.
78. Macnee W. Accelerated lung aging: A novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans 2009;37 (pt 4):819-823.
79. Lee J, Sandford A, Man P et al. Is the aging process accelerated in chronic obstructive pulmonary disease? Curr Opin Pulm Med 2011;17: 90-97.
80. Mui TS, Man JM, McElhaney JE et al. Telomere length and chronic obstructive pulmonary disease: Evidence of accelerated aging. J Am Geriatr Soc 2009;57:2372-2374.
81. Savale L, Chaouat A, Bastuji-Garin S et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:566-571.
82. Yoder MC, Ingram DA. The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: Is there common ground for understanding the roles of numerous marrowderived cells in the neoangiogenic process? Biochim Biophys Acta 2009;1796:50-54.
83. Gray K, Bennett M. Role of DNA damage in atherosclerosis - Bystander or participant? Biochem Pharmacol 2011;82:693-700.
84. Wang JC, Bennett M. Aging and atherosclerosis: Mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 2012;111:245-259.
85. Hoffmann E, Wald J, Lavu S et al. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol 2013;75:186-196.
86. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547-566.
87. Caramori G, Rigolin GM, Mazzoni F et al. Circulating endothelial stem cells are not decreased in pulmonary emphysema or COPD. Thorax 2010;65:554-555.
88. Sala E, Villena C, Balaguer C et al. Abnormal levels of circulating endothelial progenitor cells during exacerbations of COPD. Lung 2010;188:331-338.
89. Timmermans F, Plum J, Yoder MC et al. Endothelial progenitor cells: Identity defined? J Cell Mol Med 2009;13:87-102.
90. Case J, Mead LE, Bessler WK et al. Human CD341AC1331VEGFR- 21 cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007;35:1109-1118.